Crescent Biopharma (CBIO) Share-based Compensation (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Share-based Compensation of $4.0 million for Q2 2026, down 25.75% year-over-year from $5.3 million in Q2 2025, and down 3.6% quarter-over-quarter from $4.1 million in Q1 2026.
Crescent Biopharma (CBIO) Share-based Compensation (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Share-based Compensation for 14 consecutive years, with $4.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Share-based Compensation fell 25.75% year-over-year to $4.0 million; the TTM figure through Jun 2026 stood at $14.8 million (up 67.5% YoY), while the FY2025 annual figure was $13.3 million, up 183.13% from the prior year.
- Share-based Compensation fell to $4.0 million in Q2 2026 per CBIO's latest filing, from $4.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.3 million in Q2 2025 and bottomed at -$78.0 in Q1 2022.
- Historically, Share-based Compensation has averaged $1.7 million across 5 years, with a median of $1.1 million in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation sank 100.0% — and 2023, when it soared 62956.25%.
- Crescent Biopharma's Share-based Compensation stood at $899201.0 in 2022, then climbed by 1.02% to $908371.0 in 2023, then advanced by 24.84% to $1.1 million in 2024, then jumped by 318.43% to $4.7 million in 2025, then slipped by 16.44% to $4.0 million in 2026.
- Business Quant data shows CBIO's Share-based Compensation at $4.0 million in Q2 2026, $4.1 million in Q1 2026, and $4.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | 3.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.97 Mn |
| Jun 30, 2026 | 3.97 Mn |
| Mar 31, 2026 | 4.11 Mn |
| Mar 31, 2026 | 4.11 Mn |
| Dec 31, 2025 | 4.75 Mn |
| Dec 31, 2025 | 4.75 Mn |
| Sep 30, 2025 | 6.93 Mn |
| Sep 30, 2025 | 6.93 Mn |
| Jun 30, 2025 | 401,000.00 |
| Jun 30, 2025 | 401,000.00 |
| Mar 31, 2025 | 1.23 Mn |
| Mar 31, 2025 | 1.23 Mn |
| Sep 30, 2024 | 8.83 Mn |
| Sep 30, 2024 | 8.83 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.19 Mn |
| Mar 31, 2024 | 1.19 Mn |
| Dec 31, 2023 | 908,371.00 |
| Dec 31, 2023 | 908,371.00 |